Rodos BioTarget Overview
- Status
-
Out of Business
- Employees
-
2
- Latest Deal Type
-
Bankr. Admin/Reorg
Rodos BioTarget General Information
Description
Developer of nanomedicine and nanoparticles designed to achieve enhanced prophylactic and therapeutic approaches against unmet medical needs. The company's nanoparticles can change the biodistribution and pharmacokinetics of the therapeutic cargos and protect them from the in vivo environment, enabling physicians to improve the stability of the drug and enhance its target engagement.
Contact Information
Website
www.biotargeting.euCorporate Office
- Feodor-Lynen-Strasse 31
- 30625 Hanover
- Germany
Corporate Office
- Feodor-Lynen-Strasse 31
- 30625 Hanover
- Germany
Rodos BioTarget Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Bankruptcy: Admin/Reorg | 01-Aug-2021 | Completed | Generating Revenue | |||
| 8. Later Stage VC | 15-Jan-2020 | Completed | Generating Revenue | |||
| 7. Grant | 16-Oct-2017 | Completed | Generating Revenue | |||
| 6. Later Stage VC | 20-Aug-2017 | Completed | Generating Revenue | |||
| 5. Equity Crowdfunding | 18-Aug-2017 | Completed | Generating Revenue | |||
| 4. Equity Crowdfunding | 12-Nov-2016 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 01-Jan-2012 | Completed | Generating Revenue | |||
| 2. Seed Round | 29-Apr-2009 | Completed | Startup | |||
| 1. Grant | 04-Jul-2007 | $2.02K | Completed | Startup |
Rodos BioTarget Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Rodos BioTarget Patents
Rodos BioTarget Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2016298606-A1 | Immunotherapies for malignant, neurodegenerative and demyelinating diseases by the use of targeted nanocarriers | Inactive | 27-Jul-2015 | ||
| CA-2995135-A1 | Immunotherapies for malignant, neurodegenerative and demyelinating diseases by the use of targeted nanocarriers | Inactive | 27-Jul-2015 | ||
| EP-3328367-A1 | Immunotherapies for malignant, neurodegenerative and demyelinating diseases by the use of targeted nanocarriers | Inactive | 27-Jul-2015 | ||
| US-20180235992-A1 | Immunotherapies for malignant, neurodegenerative and demyelinating diseases by the use of targeted nanocarriers | Inactive | 27-Jul-2015 | ||
| WO-2017017148-A1 | Immunotherapies for malignant, neurodegenerative and demyelinating diseases by the use of targeted nanocarriers | Inactive | 27-Jul-2015 | A61K31/7068 |
Rodos BioTarget Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Rodos BioTarget FAQs
-
Where is Rodos BioTarget headquartered?
Rodos BioTarget is headquartered in Hanover, Germany.
-
What is the size of Rodos BioTarget?
Rodos BioTarget has 2 total employees.
-
What industry is Rodos BioTarget in?
Rodos BioTarget’s primary industry is Drug Delivery.
-
Is Rodos BioTarget a private or public company?
Rodos BioTarget is a Private company.
-
What is Rodos BioTarget’s current revenue?
The current revenue for Rodos BioTarget is .
-
How much funding has Rodos BioTarget raised over time?
Rodos BioTarget has raised $7.52M.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
